scispace - formally typeset
K

Kenichi Kaida

Researcher at National Defense Medical College

Publications -  86
Citations -  2414

Kenichi Kaida is an academic researcher from National Defense Medical College. The author has contributed to research in topics: Guillain-Barre syndrome & Chronic inflammatory demyelinating polyneuropathy. The author has an hindex of 23, co-authored 82 publications receiving 2042 citations. Previous affiliations of Kenichi Kaida include Saitama Medical University.

Papers
More filters
Journal ArticleDOI

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

Ivo N. van Schaik, +149 more
- 01 Jan 2018 - 
TL;DR: This study, which is to the authors' knowledge, the largest trial of CIDP to date and the first to study two administrations of immunoglobulins and two doses, showed that both doses of SCIg IgPro20 were efficacious and well tolerated, suggesting thatSCIg can be used as a maintenance treatment for C IDP.
Journal ArticleDOI

Ganglioside complexes as new target antigens in Guillain-Barré syndrome.

TL;DR: Antibodies specific for a complex of gangliosides GD1a and GD1b (GD1a/GD1b) were found in sera from eight of 100 patients with Guillain–Barré syndrome by the use of enzyme‐linked immunosorbent assay and thin‐layer chromatogram immunostaining.
Journal ArticleDOI

Anti-ganglioside complex antibodies in Miller Fisher syndrome

TL;DR: In patients with MFS not only G Q1b itself but also clustered epitopes of GSCs, including GQ1b, may be considered to be prime target antigens for serum antibodies, and a tendency to escape sensory disturbances is shown by anti-GQ1 b/GM1-positive MFS.
Journal ArticleDOI

Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial

TL;DR: The safety and efficacy of eculizumab, a humanised monoclonal antibody against the complement protein C5, in patients with severe Guillain-Barré syndrome is investigated and the primary outcome measure did not reach the predefined response rate.